AHA 2021 | CRAVE: Coffee Safety in Rhythm Disorders

On the one side, caffeine can increase arrythmias or interfere with sleeping, but on the other hand, it helps people feel more energetic and do more physical activity. 

AHA 2021 | CRAVE: Seguridad del café para los trastornos del ritmo

These data contribute to the evidence supporting the fact that people who present, or are at risk of presenting supra ventricular arrythmias or atrial fibrillation might not need to avoid coffee. 

The CRAVE study included 100 young volunteers with no prior arrythmia or heart disease who were instructed to modify caffeine intake habits in two-day blocks. 

Coffee intake did not increase atrial arrythmia, but slightly increased premature ventricular contractions. On the other hand, the day people were allowed to have coffee, they walked 1,000 more steps vs the day coffee was not allowed (p=0.001).

Coffee intake was defined as one standard cup of coffee or an expresso. 

There were no differences between having or not having coffee and the incidence of atrial arrythmia. Also, coffee consumption was associated to fewer supra ventricular tachycardia, but more premature ventricular contractions. 


Read also: AHA 2021 | PALACS: Posterior Left Pericardiotomy Improves Post-Procedural AF.


The day participants were allowed to have coffee, they slept mean 36 minutes less than abstinence day. 

Original Title: The coffee and real-time atrial and ventricular ectopy (CRAVE) trial.

Reference: presentado por Marcus GM durante las sesiones científicas del congreso de la AHA 2021.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

How real are the adverse effects of statins? Evidence from randomized clinical trials

The safety of statins continues to be a subject of debate, partly due to the extensive list of adverse effects included in prescribing information,...

Is it safe to use negative chronotropic drugs early after TAVI?

TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing prevalence over the last decade, associated with...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...